Payment overview · 2025
General Payments
$709.21
33 reported records · 12 companies
Healthcare provider profile · identity verified
Jeffrey Kim-Wayne Gin, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COVINA, CA · NPI 1225140759
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Kim-Wayne Gin, M.D. received $709.21 in general payments during 2025 across 33 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Xifaxan.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $145.24 | 20.5% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.55 | 13.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.60 | 12.8% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $79.87 | 11.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $57.22 | 8.1% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $57.07 | 8.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.62 | 6.4% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $31.92 | 4.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.89 | 4.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $26.84 | 3.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.46 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.93 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $709.21 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $145.24 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.40 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $57.22 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $57.07 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.22 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.62 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.08 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $31.92 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.89 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $26.84 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 110 |
| Lisinopril | Lisinopril | 255 | 71 |
| Metformin Hcl | Metformin Hcl | 250 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 57 |
| Omeprazole | Omeprazole | 212 | 51 |
| Alprazolam | Alprazolam | 203 | 31 |
| Ibuprofen | Ibuprofen | 193 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 178 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 165 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 156 | 17 |
| Losartan Potassium | Losartan Potassium | 148 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 36 |
| Simvastatin | Simvastatin | 123 | 36 |
| Gabapentin | Gabapentin | 121 | 29 |
| Azithromycin | Azithromycin | 107 | 69 |
| Furosemide | Furosemide | 105 | 37 |
| Trazodone Hcl | Trazodone Hcl | 105 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 19 |
| Lorazepam | Lorazepam | 85 | 15 |
| Tramadol Hcl | Tramadol Hcl | 80 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 24 |
| Ozempic | Semaglutide | 73 | 15 |
| Methylprednisolone | Methylprednisolone | 72 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 18 |
| Glipizide | Glipizide | 67 | 21 |
| Atenolol | Atenolol | 66 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 19 |
| Mirtazapine | Mirtazapine | 58 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 55 | 17 |
| Carvedilol | Carvedilol | 53 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 49 | 14 |
| Famotidine | Famotidine | 49 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 47 | 11 |
| Eliquis | Apixaban | 46 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Baclofen | Baclofen | 44 | 13 |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Cephalexin | Cephalexin | 42 | 24 |
| Finasteride | Finasteride | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 11 |
| Ondansetron Odt | Ondansetron | 38 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 12 |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | 11 |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Xifaxan | Rifaximin | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $709.21 · 33 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | ABRYSVO, AIRSUPRA, COMIRNATY, FREESTYLE LIBRE 3, JARDIANCE, JOURNAVX, KRYSTEXXA, OTEZLA, Ozempic, PREVNAR 20, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Wegovy, XIFAXAN, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error